Noile-Immune Biotech
Tokyo, Japan· Est.
A biotech developing tumor microenvironment-activated cytokine therapies for cancer.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A biotech developing tumor microenvironment-activated cytokine therapies for cancer.
OncologyImmunology
Technology Platform
A protein engineering platform to create conditionally active biologics, such as cytokines, that are designed to be selectively activated by the tumor microenvironment to minimize systemic toxicity.
Opportunities
The platform could enable the safe use of highly potent cytokines, opening a new therapeutic class in immuno-oncology and creating significant partnership or acquisition potential with large pharma.
Risk Factors
High technical risk in achieving sufficient tumor-selective activation and efficacy; intense competition from other biotechs and pharma companies in the masked cytokine space.
Competitive Landscape
Competes with CytomX Therapeutics and other biotechs developing tumor-microenvironment activated therapies; differentiation hinges on specific engineering of its cytokine constructs and preclinical data.